More than 3 million U.S. people with solid tumors could potentially benefit from Abbott's new test
More than 3 million U.S. people with solid tumors could potentially benefit from Abbott's new test Stock Titan
Covered in this story
What has happened since
- Abbott Laboratories is down 1.3% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- TD Cowen: $117 → $135 by Aug 2027 · Buy via Investing.com India
- UBS: $107 → $125 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 50 stories mentioning Abbott Laboratories, the earliest published 22 Jan 2026.
Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.